Akio Nakajima
- Rheumatology top 5%
- IgG4-Related and Inflammatory Diseases 5
- Hematology top 10%
- Multiple Myeloma Research and Treatments 4
-
- Neuroendocrine Tumor Research Advances 4
-
- Gastrointestinal disorders and treatments 4
-
- Spinal Cord Injury Research 3
-
- CNS Lymphoma Diagnosis and Treatment 2
-
- Histiocytic Disorders and Treatments 2
-
- Ubiquitin and proteasome pathways 2
- Co-authors
- Hisanori UmeharaTakuji NakamuraMasao TanakaTakafumi KawanamiMitsuhiro KawanoTomoyuki SakaiYasufumi MasakiMiyuki Miki
- Cited by
- RheumatologyHematologyOncology
In The Last Decade
Akio Nakajima
29 papers receiving 699 citations
Peers
Comparison fields: 5 of 85
- Rheumatology 306
- Hematology 90
- Oncology 176
- Epidemiology 212
- Surgery 242
Countries citing papers authored by Akio Nakajima
This map shows the geographic impact of Akio Nakajima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akio Nakajima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akio Nakajima more than expected).
Fields of papers citing papers by Akio Nakajima
This network shows the impact of papers produced by Akio Nakajima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akio Nakajima. The network helps show where Akio Nakajima may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Akio Nakajima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 1 | |
| 2 | 2015 | 11 | |
| 3 | 2014 | 33 | |
| 4 | 2013 | 72 | |
| 5 | 2012 | 35 | |
| 6 | 2012 | 2 | |
| 7 | 2012 | 23 | |
| 8 | Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. | 2012 | 11 |
| 9 | [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report]. | 2012 | 2 |
| 10 | 2011 | 13 | |
| 11 | 2011 | 4 | |
| 12 | Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. | 2011 | 54 |
| 13 | [Primary neurolymphomatosis of the cervical nerve root]. | 2010 | 2 |
| 14 | Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas. | 2010 | 5 |
| 15 | 2009 | 38 | |
| 16 | 2008 | 13 | |
| 17 | 1997 | 2 | |
| 18 | 1992 | 36 | |
| 19 | 1989 | 25 | |
| 20 | 1988 | 20 |
About Akio Nakajima
Akio Nakajima is a scholar working on Hematology, Rheumatology and Oncology, having authored 29 papers that have together received 717 indexed citations. Recurring topics across this work include IgG4-Related and Inflammatory Diseases (5 papers), Gastrointestinal disorders and treatments (4 papers), Multiple Myeloma Research and Treatments (4 papers), Neuroendocrine Tumor Research Advances (4 papers), Spinal Cord Injury Research (3 papers), CNS Lymphoma Diagnosis and Treatment (2 papers), Histiocytic Disorders and Treatments (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Rheumatology (306 citations), Hematology (90 citations) and Oncology (176 citations). Akio Nakajima has collaborated with scholars based in Japan, Canada and China. Frequent co-authors include Hisanori Umehara, Takuji Nakamura, Masao Tanaka, Takafumi Kawanami, Mitsuhiro Kawano, Tomoyuki Sakai, Yasufumi Masaki, Miyuki Miki, Yoshimasa Fujita and Tsuneyo Mimori.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.